Sensex and Nifty extended their gains for the fifth consecutive session on Budget day, driven by expectations of income tax cuts to boost consumption. Sun Pharma led the gains with a 15% rise in Q3 ...

Sun Pharma reported a 15 percent on-year growth in its consolidated net profit to Rs 2,903.4 crore for Q3 FY25. The company’s revenue rose 10 percent on-year to Rs 13,675.5 crore for the ...

Sun Pharmaceutical Industries has elevated Aalok Shanghvi, son of the drugmaker’s founder promoter Dilip Shanghvi, as the Chief Operating Officer. Aalok (40 years), continues as Whole-time ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Janux Therapeutics Inc (JANX – Research Report), ...

Shares of Sun Pharmaceutical Industries Ltd. 524715 rallied 1.56% to 1,767.05 Indian rupees Tuesday, on what proved to be an all-around great trading session for the stock market, with the BSE ...

Sun Pharmaceutical Industries Ltd. 524715 shares inched down 0.16% to 1,739.95 Indian rupees Monday, on what proved to be an all-around grim trading session for the stock market, with the BSE ...

Sun Pharma (SUNP) Q3FY25 EBIDTA (+20% YoY) adjusted for milestone was largely in line with our estimates, aided by higher specialty and domestic formulation sales. Overall specialty sales ...

It declared an interim dividend of Rs 5 per share. Sun Pharmaceuticals Industries: The drug major reported a 15 per cent YoY growth in its net profit at Rs 2,903.4 crore, while revenue inched up ...

Indian stock markets are open today, Saturday, February 1, due to Budget Day. In the previous session on Friday, benchmark indices extended their winning streak to four consecutive sessions ...

New Delhi: Sun Pharmaceutical Industries reported a 15 percent on-year increase in consolidated net profit, reaching Rs 2,903 crore for the December quarter, driven by strong sales across geographies.

Emerging markets business contributes about 18% to Sun Pharma’s global revenues. Subsequently, he took additional charge of global generic R&D, global business development (generics), operations and ...